According to the market research report “Neuroblastoma Treatment Market: By Drug (Xalkori, Clafen, Vincasar PFS) By Treatment (Surgery, Chemotherapy, High-dose chemotherapy with stem cell support, Monoclonal antibody treatment, Radiotherapy) & Geography-Forecast (2016-2021)”, published by IndustryARC, estimates that North America will retain dominant share till 2021.
The Neuroblastoma Treatment Market focuses on the treatment of the most well-known cancer variant which is usually found in newborns. It is caused because of embryonal damage of the nervous system which emerges from the neuroblasts. This malignancy mutates in the nerve tissues of the chest or spine. A variety of therapeutics or medications have been appropriated to battle the metastatic neuroblastoma, like immunotherapy, and chemotherapy. The need for neuroblastoma treatment is primarily driven by the rising number of cancer patients around the world. Burgeoning medical services costs is another key factor to drive the requirement for neuroblastoma management. In any case, certain issues like high cost of this type of cancer treatment is predicted to hamper the development of the Neuroblastoma Treatment Market. The U.S. leads the way with around 700 new neuroblastoma cases each year.
Scope & Regional Forecast of the Neuroblastoma Treatment Market
North America currently plays the biggest part in driving neuroblastoma research. The expanding number of FDA approvals for innovative treatments and high R&D investments are the key development drivers. Currently, patients suffering from this type of cancer only have a 60% chance of survival. This is expected to rise as advances in genomic screening, precision medicine, double stem-cell transplant and gene therapy expand the boundaries of healthcare knowledge.
Out of all prospective treatments, genetic screening has already established itself as a force to be reckoned with. Human trials of the treatment are going along well and in many cases the swelling caused by the tumour has subsided. Precision medicine is also playing its part in the success of this procedure. Once the genetic sequence of the tumor is obtained, a particular drug is being administered to deal with any changes.
Make an Inquiry @ http://industryarc.com/inquiry-before-buying.php?id=16073
When compared to the double stem-cell transplant, genetic screening feels almost benign. Such a transplant is considered to be the most aggressive and toxic procedure for a child suffering from cancer to experience. A more pro-active and less toxic alternative is gene therapy. Although it is currently in development, it is considered to be a very strong tool for easily inserting the ‘right’ or normal genes into the genome. Thus, the future of the Neuroblastoma Treatment Market is exciting with several procedures in the pipeline and being readied for mass consumption.
Segmentations & Key Players Involved in the Neuroblastoma Treatment Market
The Neuroblastoma Treatment Market can be broken down into various segmentations on the basis of –
Drug: Xalkori (crizotinib), Adriamycin PFS (Doxorubicin Hydrochloride), Clafen (Cyclophosphamide), Vincasar PFS (Vincristine Sulfate) and Others.
Treatment: Surgery, Chemotherapy, High-dose chemotherapy with stem cell support, Monoclonal antibody treatment, Radiotherapy and Others.
Geography: Europe, Asia-Pacific, North America and Rest of the World.
Some of the key players involved in the Neuroblastoma Treatment Market are as follows:
GL Pharm Tech Corporation
Hôpitaux de ParisOthers
Erasmus Medical Center
Assistance Publique – Hopitaux de Paris
Texas Neurofibromatosis Foundation
Request For Table Of Content @ http://www.industryarc.com/pdfdownload.php?id=16073
Why buy this report?
* The overall market has been consolidated from the perspective of different geographic locations and key economies for this market.
* Identifies growth sectors and factors driving or constraining the market.
* The market is analyzed based on the key attributes such as the power in the hands of producers and consumers, analysis on the degree of competition, and threats from substitutes and new entrants.
* The study includes the demand of this particular market on a global and regional scale for a five year period of 2016 – 2021, to assess how the market will develop.
IndustryARC is a Research and consulting firm that publishes more than 500 Reports Annually in various industries, such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences & Healthcare.
IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications of the Market. Our Custom Research Services are designed to provide insights on the constant flux in the global demand-supply gap of markets. Our strong analyst team enables us to meet the client research needs at a very quick speed with a variety of options for your business.
We look forward to support the client to be able to better address customer needs; stay ahead in the market; become the top competitor and get real-time recommendations on business strategies and deals. Contact us to find out how we can help you today.